Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, scheduled for May 20-21, 2026. The company’s presentation will begin at 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one investor meetings planned throughout the conference.
The announcement provides Oragenics with a platform to showcase its proprietary intranasal delivery technology and its lead candidate, ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is preparing to commence clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. Beyond concussion, Oragenics’ intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
This presentation is significant for investors as it offers insight into the company’s clinical development progress and its strategy to address unmet medical needs in neurological care. The Sidoti conference is a key event for micro-cap companies to connect with the investment community, and Oragenics’ participation could increase visibility and attract potential partners or investors. For more details, the full press release is available at https://ibn.fm/MLd0Y.
Oragenics is committed to developing innovative therapies for neurological conditions, and its intranasal delivery platform represents a novel approach to targeting the brain. The company’s focus on concussion is particularly timely, given the growing awareness of the long-term effects of traumatic brain injuries in sports and military contexts. Successful development of ONP-002 could provide a much-needed treatment option for millions of people affected by concussions annually.
Investors will be watching for updates on the Australian clinical trial initiation and any data that may emerge from early-stage studies. The company’s ability to progress through clinical milestones will be critical for its valuation and future funding. Oragenics’ presentation at the Sidoti conference offers a chance for the company to articulate its vision and progress directly to the investment community. For ongoing updates, investors can visit the company’s newsroom at https://ibn.fm/OGEN.
